Producción CyT
ASV2021 - Use of IgG serology as a complement to diagnosis and severity biomarker in SARS-Cov-2 infection
Congreso
Autoría:
Castello A.A. ; Iglesias G. ; Mandile M.G. ; Peri Ibañez E. ; Ramirez C. ; Rahhal M. ; Silvestre D. ; Zubieta M. ; Alluisette M. ; Curvale C. ; Laje S. ; Bodega F. ; Argüelles M. ; TEMPRANA, CARLOS FACUNDO ; Glikmann G.Fecha:
2021Editorial y Lugar de Edición:
University of Michigan Medical SchoolResumen *
Determination of specific circulating IgG during and after a viral infection is useful indiagnosis, prevalence and vaccine studies. We determine SARS Cov-2 specific IgG titers at different timepoints along the course of the infection in order to look for confirmation of initial molecular diagnosis andputative correlations between titers and disease severity. Methods: 157 plasma samples from ambulatory asymptomatic or pauci-symptomatic patients attending and234 samples from severe patients admitted to intermediate and intensive care services were collected andstored at -80 ° C. The plasmas were analyzed by ELISA Covidar IgG (Lemos SA) qualitatively and selectedsamples were quantified obtaining their end point titer. Results: IgG is detectable in plasma from the first week of symptom onset in patients with different clinicalpresentations. The titres show significant differences (p <0.00001) between patients with mild to moderate symptoms andsevere presentations, the maximum levels of the latter being up to 10 times higher than the former. The follow-ups of IgG titers in severe presentations show similar patterns with a peak between 20 and 40 daysafter the onset of symptoms and a marked decline thereafter (Fig 1) Among hospitalized cases the titres between days 15 and 30 post onset show significant differences (StudentT = 0,006) between outcomes (discharge or deaths). The finding of several patients without detectable levels of IgG suggests that there is the possibility of falsepositives in molecular detection among our population. Conclusions: Specific IgG should be used to support and confirm the molecular diagnosis. IgG quantification is useful as amarker of severity discriminating ambulatory and hospitalized cases, but even among hospitalized cases thetitres between days 15 and 30 post onset show significant differences between outcomes (discharge ordeaths). We are increasing the number of follow-ups in order to confirm the usefulness of IgG quantification asa prognostic marker and the role of IgG as a mediator of immunopathology. Información suministrada por el agente en SIGEVAPalabras Clave
IgGSARS-COV-2SEROLOGYCOVID